Paclitaxel Treatment Options in United Kingdom (Updated 8/25)

STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)

NCT01927068

Completed

Cohort 1: Single-Arm, multicenter study to continue to assess the safety and performance of the Stellarex 035 Drug Coated Balloon (formerly known as the Cardiovascular Ingenuity (CVI) Paclitaxel-Coated PTA Balloon Catheter) in the treatment of de novo or restenotic lesions in the superficial femoral and/or popliteal arteries. Cohort 2: To evaluate this patient population for treatment of in-stent restenotic lesions.

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

03/22/2023

Locations: The Wesley St. Andrew Research Institute Ltd., Auchenflower, Not set +43 locations

The Wesley St. Andrew Research Institute Ltd., Auchenflower, Not set

Flinders Medical Centre, Bedford, Not set

Royal Brisbane and Women's Hospital, Brisbane, Not set

Monash Medical Centre at Dandenong Campus, Dandenong, Not set

The Alfred Hospital, Melbourne, Not set

Sir Charles Gairdner Hospital, Nedlands, Not set

Medizinische Universität Graz - Univ. Klinik für Innere Medizin, Graz, Not set

Onze Lieve Vrouw Ziekenhuis, Aalst, Not set

Middelheim Hospital, Antwerpen, Not set

Imelda Hospital, Bonheiden, Not set

AZ Sint-Blasius, Dendermonde, Not set

ZOL Campus Sint Jan, Genk, Not set

Universitair Ziekenhuis Gent, Gent, Not set

University Clinic Leuven, Leuven, Not set

Regionaal Ziekenhuis Heilig Hart Tienen, Campus Mariëndal - MCT, Vascular Surgery Department, Tienen, Not set

CHU de Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, Not set

CHU de Lyon, Hôpital Edouard Herriot, Lyon, Not set

Hopital de Ia Timone, Marseille, Not set

CHU de Nantes, Hôpital Nord Laennec, Nantes, Not set

Hôpital Européen georges Pompidou, Paris, Not set

CHU de Rennes, Hôpital Pontchaillou, Rennes, Not set

Clinique Pasteur, Toulouse, Not set

Universitats-Herzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Not set

Jüdisches Krankenhaus Berlin, Berlin, Not set

Medizinische Universitätsklinik III, Heidelberg, Not set

Klinikum Immenstadt, Herz-und Gefässzentrum Oberallgäu-Kempten, Immenstadt, Not set

SRH Klinikum Karlsbad-Langensteinbach, Langensteinbach, Not set

University Leipzig Medical Center, Leipzig, Not set

RoMed Klinikum Rosenheim, Rosenheim, Not set

Universitatsklinik, Abteilung Für Diagnostische und Inverventionelle Radiologie, Tübingen, Not set

Ospedali Riuniti - SOD, Ancona, Not set

Villa Maria Eleonora Hospital, Palermo, Not set

S.C. Chirurgia Vascolare ed Endovascolare, Perugia, Not set

Auckland City Hospital, Auckland, Not set

Middlemore Hospital, Auckland, Not set

Waikato Hospital, Hamilton, Not set

Wellington Hospital, Wellington, Not set

Uniwersyteckie Centrum Kliniczne, Gdańsk, Not set

Instytut Hematologii i Transfuzjologii, Warszawa, Not set

Centre d'Atencio Integral Hospital Dos de Maig, Barcelona, Not set

Hospital Universitario Quirón de Madrid, Madrid, Not set

Imperial College Academic and Healthcare NHS Trust, St. Mary's Hospital, London, Not set

King's College, London, Not set

UCL Division of Surgery and Interventional Science, London, Not set

Conditions: Peripheral Arterial Disease

Register for Updates

Learn More ›

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

NCT02322814

Terminated

This three-cohort, multi-stage, randomized, Phase II, multicenter trial will evaluate the safety and tolerability and estimate the efficacy of cobimetinib plus paclitaxel versus placebo plus paclitaxel in Cohort I, of cobimetinib plus atezolizumab plus paclitaxel in Cohort II, and of cobimetinib plus atezolizumab plus nab-paclitaxel in Cohort III in participants with metastatic or locally advanced, triple-negative adenocarcinoma of the breast who have not received prior systemic therapy for meta... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/16/2023

Locations: Cancer Specialists of North Florida, Jacksonville, Florida +52 locations

Cancer Specialists of North Florida, Jacksonville, Florida

Mercy Hospital, a Campus of Plantation General Hospital, Miami, Florida

Florida Hospital Cancer Inst, Orlando, Florida

Florida Cancer Research Institute, Plantation, Florida

Cancer Treatment Centers of America, Newnan, Georgia

Ingalls Memorial Hospital, Harvey, Illinois

Montefiore Einstein Cancer Center, Bronx, New York

Magee Womens Hospital, Pittsburgh, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

Avera Cancer Institute, Sioux Falls, South Dakota

Northwest Medical Specialties, Tacoma, Washington

Calvary Mater Newcastle, Waratah, New South Wales

Mater Adult Hospital, South Brisbane, Queensland

Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria

St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia

Clinique Edith Cavell, Bruxelles, Not set

AZ Sint Lucas (Sint Lucas), Gent, Not set

Jessa Zkh (Campus Virga Jesse), Hasselt, Not set

AZ Groeninge, Kortrijk, Not set

AZ Sint Augustinus Veurne, Veurne, Not set

Fakultni nemocnice Hradec Kralove, Hradec Kralove, Not set

Multiscan s.r.o., Pardubice, Not set

Centre Oscar Lambret, Lille, Not set

Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier, Not set

Hopital Tenon, Paris, Not set

Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer, Rennes, Not set

Chaim Sheba Medical Center, Ramat Gan, Not set

Azienda Ospedaliero Universitaria Seconda Università Degli Studi Di Napoli, Napoli, Campania

A.O.U Policlinico S. Orsola Malpighi di Bologna U.O di Medicina Interna Borghi - Pad.2, Bologna, Emilia-Romagna

Centro Di Riferimento Oncologico; SOC Oncologia Medica C, Aviano, Friuli-Venezia Giulia

Policlinico Universitario Agostino Gemelli, Roma, Lazio

Istituto Europeo Di Oncologia, Milano, Lombardia

Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria ? Polo Oncologico, Pisa, Toscana

National Cancer Center; Medical Oncology, Gyeonggi-do, Not set

Asan Medical Center, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

Yonsei University Health System/Severance Hospital, Seoul, Not set

Pauls Stradins Clinical University Hospital, R?ga, Not set

Riga East Clinical University Hospital Latvian Oncology Centre, Riga, Not set

Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Not set

Oncology Center Sf. Nectarie, Craiova, Not set

Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona

Organización Sanitaria Integrada Bilbao Basurto, Bilbao, Vizcaya

Hospital Universitario Infanta Cristina; Servicio de Oncologia, Badajoz, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid, Not set

Hospital Clinico San Carlos; Servicio de Nefrologia, Madrid, Not set

Hosp. Regional Univ. de Malaga ? Hospital Materno Infantil; Hospital Materno Infantil de Malaga, Malaga, Not set

Chang Gung Memorial Hospital, Kaohsiung Country, Not set

Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Not set

Nuffield Health Bournemouth Hospital, Bournemouth, Not set

Mount Vernon Hospital, Middlesex, Not set

Nottingham University Hospitals City Campus, Nottingham, Not set

Conditions: Breast Cancer

Register for Updates

Learn More ›

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

NCT02983045

Completed

In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further asses... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/09/2023

Locations: UCSD, Moores Cancer Center, La Jolla, California +57 locations

UCSD, Moores Cancer Center, La Jolla, California

UCLA, Los Angeles, California

Stanford Cancer Institute, Stanford, California

University of Colorado, Denver, Denver, Colorado

Yale School of Medicine, New Haven, Connecticut

University of Florida, Gainesville, Florida

Orlando Health Inc., Orlando, Florida

Emory University Hospital, Atlanta, Georgia

Loyola University Medical Center, Chicago, Maywood, Illinois

Indiana University Health Melvin & Bren Simon Cancer Center, Indianapolis, Indiana

University of Kansas Cancer Center, Kansas City, Kansas

Dana-Farber Cancer Institute, Boston, Massachusetts

Henry Ford Hospital, Detroit, Michigan

Washington University School of Medicine in St. Louis, Saint Louis, Missouri

Roswell Park Cancer Institute, Buffalo, New York

New York University Langone Medical Center - NYU Cancer Institute, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Providence Portland Medical Center, Portland, Oregon

The University of Texas MD Anderson Cancer Center, Houston, Texas

Inova Fairfax Hospital, Fairfax, Virginia

Virginia Cancer Specialists, PC, Fairfax, Virginia

Seattle Cancer Care Alliance, Seattle, Washington

Antwerp University Hospital, Edegem, Not set

Vzw Az Groeninge, Kortrijk, Not set

UZ Leuven, Leuven, Not set

CHU de Liège, Liège, Not set

GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, Not set

BC Cancer Agency Vancouver Centre, Vancouver, British Columbia

Sunnybrook Health Sciences Centre, Toronto, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

Jewish General Hospital, Montréal, Quebec

L'Institut Paoli - Calmettes, Marseille, Brouches-duRhone

Institut de Cancerologie de l'Ouest, Saint-Herblain, Loire-Atlantique

Centre Léon Bérard, Lyon, Not set

Assistance Publique Hopitaux de Marseille - Hopital Nord, Marseille Cedex 20, Not set

Gustave Roussy, Villejuif, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

Istituto Europeo di Oncologia, Milano, Not set

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli, Not set

Azienda Ospedaliera San Camillo-Forlanini, Roma, Not set

Azienda Ospedaliera Universitaria Senese, Siena, Not set

Institute for Cancer Research and Treatment (IRCC), Turin, Not set

Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza, Brzozów, Not set

Szpitale Pomorskie Sp. z o.o., Gdynia, Not set

Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock, Not set

Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznań, Not set

Med-Polonia Sp. z o.o., Poznań, Not set

Instytut Medyczny Santa Familia Sp. z o. o. w Łodzi, Łódź, Not set

Hospital Quirón Barcelona, Barcelona, Not set

Hospital Clínic de Barcelona, Barcelona, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Not set

Clínica Universidad de Navarra, Pamplona, Not set

Campus Hospital Universitario Virgen del Rocío - Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Not set

The Royal Marsden NHS Trust, London, Not set

Mount Vernon Cancer Centre, Northwood, Not set

The Christie NHS Foundation Trust, Withington, Not set

Conditions: Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer

Register for Updates

Learn More ›

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

NCT02041533

Completed

The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/02/2023

Locations: Southern Cancer Center, Inc., Mobile, Alabama +140 locations

Southern Cancer Center, Inc., Mobile, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

Local Institution - 0034, Tucson, Arizona

Local Institution - 0016, Stanford, California

University Of Colorado Hosp, Aurora, Colorado

Local Institution - 0020, New Haven, Connecticut

Local Institution - 0030, Miami, Florida

Local Institution - 0033, Ocala, Florida

H. Lee Moffitt Cancer Center, Tampa, Florida

Local Institution - 0010, Atlanta, Georgia

Northwest Georgia Oncology Center, P.C., Marietta, Georgia

Local Institution - 0037, Chicago, Illinois

Local Institution - 0014, Lexington, Kentucky

Crescent City Research Consortium, LLC, Marrero, Louisiana

Local Institution - 0024, Baltimore, Maryland

Local Institution - 0036, Boston, Massachusetts

Local Institution - 0070, Boston, Massachusetts

Roswell Park Cancer Institute, Buffalo, New York

Local Institution - 0009, New York, New York

Local Institution - 0005, New York, New York

University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina

Local Institution - 0003, Durham, North Carolina

Local Institution - 0012, Cleveland, Ohio

Local Institution - 0027, Columbus, Ohio

Oregon Health & Science University, Portland, Oregon

Local Institution - 0007, Allentown, Pennsylvania

Local Institution - 0054, Philadelphia, Pennsylvania

Local Institution - 0002, Philadelphia, Pennsylvania

Local Institution - 0018, Pittsburgh, Pennsylvania

Local Institution - 0011, Charleston, South Carolina

Local Institution - 0038, Greenville, South Carolina

Local Institution - 0008, Nashville, Tennessee

Local Institution - 0006, Dallas, Texas

Local Institution - 0023, Houston, Texas

Cancer Centers of South Texas, San Antonio, Texas

Local Institution - 0029, Yakima, Washington

Local Institution - 0051, Berazategui, Buenos Aires

Local Institution - 0049, Capital Federal, Buenos Aires

Local Institution - 0052, Ciudad Autonoma De Buenos Aire, Buenos Aires

Local Institution - 0048, Cordoba, Not set

Local Institution - 0050, Cordoba, Not set

Local Institution - 0090, Camperdown, New South Wales

Local Institution - 0091, Brisbane, Queensland

Local Institution - 0071, Elizabeth Vale, South Australia

Local Institution - 0072, Fitzroy, Victoria

Local Institution - 0104, Heidelberg, Victoria

Local Institution - 0088, Wels, Not set

Local Institution - 0087, Wien, Not set

Local Institution - 0044, Brussels, Not set

Local Institution - 0055, Edegem, Not set

Local Institution - 0056, Gent, Not set

Local Institution - 0062, Leuven, Not set

Local Institution - 0134, Ijui, Rio Grande Do Sul

Local Institution - 0133, Porto Alegre, Rio Grande Do Sul

Local Institution - 0135, Barretos, Sao Paulo

Local Institution - 0086, Calgary, Alberta

Local Institution - 0115, Hamilton, Ontario

Local Institution - 0113, Toronto, Ontario

Local Institution - 0110, Montreal, Quebec

Local Institution - 0109, Rimouski, Quebec

Local Institution - 0059, Olomouc, Not set

Local Institution - 0061, Ostrava - Poruba, Not set

Local Institution - 0058, Praha 8, Not set

Local Institution - 0060, Usti nad Labem, Not set

Local Institution - 0120, Helsinki, Not set

Local Institution - 0119, Tampere, Not set

Local Institution - 0118, Vaasa, Not set

Local Institution - 0123, Caen, Not set

Local Institution - 0105, Lille, Not set

Local Institution - 0102, Marseille Cedex 20, Not set

Local Institution - 0167, Pontoise Cedex, Not set

Local Institution - 0100, Rennes Cedex 9, Not set

Local Institution - 0140, Strasbourg, Not set

Local Institution - 0074, Bamberg, Not set

Local Institution - 0065, Grosshansdorf, Not set

Local Institution - 0064, Heidelberg, Not set

Local Institution - 0063, Koeln, Not set

Local Institution - 0066, Stuttgart, Not set

Local Institution - 0092, Wiesbaden, Not set

Local Institution - 0073, Heraklion, Creta

Local Institution - 0075, Athens, Not set

Local Institution - 0126, Budapest, Not set

Local Institution - 0116, Debrecen, Not set

Local Institution - 0094, Matrahaza, Not set

Local Institution - 0084, Avellino, Not set

Local Institution - 0079, Livorno, Not set

Local Institution - 0143, Milano, Not set

Local Institution - 0142, Napoli, Not set

Local Institution - 0083, Perugia, Not set

Local Institution - 0082, Terni, Not set

Local Institution - 0161, Nagoya-shi, Aichi

Local Institution - 0146, Nagoya, Aichi

Local Institution - 0148, Matsuyama-shi, Ehime

Local Institution - 0153, Kobe City, Hyogo

Local Institution - 0144, Natori-shi, Miyagi

Local Institution - 0151, Niigata-shi, Niigata

Local Institution - 0166, Habikino-shi, Osaka

Local Institution - 0147, Miyakojima-ku, Osaka

Local Institution - 0145, Osaka-sayama, Osaka

Local Institution - 0152, Sakai, Osaka

Local Institution - 0150, Kitaadachi-gun, Saitama

Local Institution - 0149, Sunto-gun, Shizuoka

Local Institution - 0154, Chuo-ku, Tokyo

Local Institution - 0159, Akashi, Hyogo, Not set

Local Institution - 0162, Ota, Gunma, Not set

Local Institution - 0165, Sapporo, Hokkaido, Not set

Local Institution - 0160, Tokyo, Not set

Local Institution - 0158, Wakayama, Not set

Local Institution - 0155, Gangnam-gu, Not set

Local Institution - 0164, Seoul, Not set

Local Institution - 0163, Seoul, Not set

Local Institution - 0117, Mexico, Distrito Federal

Local Institution - 0122, Guadalajara, Jalisco

Local Institution - 0124, Merida, Yucatan

Local Institution - 0045, Amsterdam, Not set

Local Institution - 0057, Groningen, Not set

Local Institution - 0046, Rotterdam, Not set

Local Institution - 0114, Bydgoszcz, Not set

Local Institution - 0131, Krakow, Not set

Local Institution - 0139, Lodz, Not set

Local Institution - 0089, Warszawa, Not set

Local Institution - 0093, Wodzislaw Slaski, Not set

Local Institution - 0068, Cluj Napoca, Not set

Local Institution - 0067, Cluj-napoca, Not set

Local Institution - 0069, Ploiesti, Not set

Local Institution - 0040, Barcelona, Not set

Local Institution - 0041, Las Palmas De Gran Canaria, Not set

Local Institution - 0047, Madrid, Not set

Local Institution - 0042, Malaga, Not set

Local Institution - 0039, Sevilla, Not set

Local Institution - 0043, Valencia, Not set

Local Institution - 0127, Stockholm, Not set

Local Institution - 0125, Uppsala, Not set

Local Institution - 0076, Chur, Not set

Local Institution - 0077, Lausanne, Not set

Local Institution - 0078, Zuerich, Not set

Local Institution - 0157, Taipei, Not set

Local Institution - 0130, Kayseri, Not set

Local Institution - 0098, London, Greater London

Local Institution - 0097, Manchester, Greater Manchester

Local Institution - 0053, Leeds, Yorkshire

Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer

Register for Updates

Learn More ›

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients

NCT01625286

Completed

The purpose of this study is to investigate the safety and efficacy of different doses and schedules of AZD5363, when in combination with paclitaxel, in treatment of patients with advanced or metastatic breast cancer. Also to investigate a selected dose and schedule of AZD5363 in combination with paclitaxel vs. paclitaxel in combination with placebo in treatment of patients with estrogen receptor-positive advanced or metastatic breast cancer, including a subgroup who have the phosphoinositide-3-... Read More

Gender:

FEMALE

Ages:

Between 18 years and 130 years

Trial Updated:

12/23/2022

Locations: Research Site, Plovdiv, Not set +40 locations

Research Site, Plovdiv, Not set

Research Site, Sofia, Not set

Research Site, Calgary, Alberta

Research Site, Ottawa, Ontario

Research Site, Montreal, Quebec

Research Site, Quebec, Not set

Research Site, Brno, Not set

Research Site, Paris Cedex 5, Not set

Research Site, Pierre Benite CEDEX, Not set

Research Site, Villejuif, Not set

Research Site, Chiba-shi, Not set

Research Site, Chuo-ku, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Mitaka-shi, Not set

Research Site, Oita-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Seongnam-si, Not set

Research Site, Seoul, Not set

Research Site, Estado de México, Not set

Research Site, Juchitan, Not set

Research Site, Monterrey, Not set

Research Site, Oaxaca, Not set

Research Site, Lima, Not set

Research Site, Miraflores, Not set

Research Site, Singapore, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Malaga, Not set

Research Site, Valencia, Not set

Research Site, Glasgow, Not set

Research Site, Leicester, Not set

Research Site, London, Not set

Research Site, Manchester, Not set

Research Site, Plymouth, Not set

Research Site, Sutton, Not set

Conditions: Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer

Register for Updates

Learn More ›

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

NCT03150576

Recruiting

This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).

Gender:

ALL

Ages:

Between 16 years and 70 years

Trial Updated:

11/09/2022

Locations: Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge, Cambridge, Cambridgeshire +29 locations

Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge, Cambridge, Cambridgeshire

Queen's Hospital, Burton Upon Trent, Derby

The Christie, Manchester, Lancs

Pinderfields General Hospital, Wakefield, Yorkshire

University Hospital Ayr, Ayr, Not set

Basingstoke and North Hampshire Hospital, Basingstoke, Not set

Bedford General Hospital, Bedford, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Bristol Haematology & Cancer Centre, Bristol, Not set

West Suffolk Hospital, Bury Saint Edmunds, Not set

Velindre Cancer Centre, Cardiff, Not set

Colchester General Hospital, Colchester, Not set

Russells Hall Hospital, Dudley, Not set

Hinchingbrooke Hospital, Huntingdon, Not set

Ipswich Hospital, Ipswich, Not set

Kidderminster General Hospital, Kidderminster, Not set

University Hospital Crosshouse, Kilmarnock, Not set

University College London Hospital, London, Not set

Royal Free Hospital, London, Not set

Mount Vernon Cancer Centre, Northwood, Not set

Nottingham City Hospital, Nottingham, Not set

Churchill Hospital, Oxford, Not set

Peterborough City Hospital, Peterborough, Not set

Poole Hospital, Poole, Not set

The Alexandra Hopsital, Redditch, Not set

Queen's Hospital, Romford, Not set

Southampton General Hospital, Southampton, Not set

Singleton Hospital, Swansea, Not set

Royal Hampshire County Hospital, Winchester, Not set

Worcestershire Royal Hospital, Worcester, Not set

Conditions: Breast Cancer

Register for Updates

Learn More ›

TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon

NCT03913832

Unknown

The study is a prospective, multinational (Italy, Ireland and UK), multicenter, randomised Clinical Trial that compares the efficacy and performance of two drug coated balloon (DCB), the MAGIC TOUCH sirolimus coated balloon (Concept Medical) and SeQuent Please paclitaxel coated balloon (B Braun). The objective of the study is to compare angiographic outcomes of Magic TouchTM sirolimus coated balloon (Concept Medical) versus SeQuentTM paclitaxel coated balloon (Bbraun) for the treatment of de nov... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/03/2022

Locations: Galway University Hospital, Galway, Not set +5 locations

Conditions: Coronary Artery Disease, DCB

Register for Updates

Learn More ›

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

NCT01726452

Completed

This is a multicentre phase III open-labelled, randomised controlled trial. Eligible patients will be randomised in a 1:1 fashion between neoadjuvant and adjuvant chemotherapy (Investigator's choice modified MAGIC (ECF/ECX or EOF/EOX) or FLOT regimen) and surgery or Arm B (CROSS protocol: chemotherapy with radiation therapy and surgery as per multimodal protocol). Primary Objective: To evaluate one, two and three year survival of patients treated with resection plus neoadjuvant and adjuvant ch... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/29/2022

Locations: Rigshospitalet, Blegdamsvej 9, Not set +28 locations

Rigshospitalet, Blegdamsvej 9, Not set

Centre Hospitalier Régional, Universitaire de Lille 2 Avenue Oscar Lambret, 59000, Lille, Not set

Cork University Hospital, Cork, Not set

Beaumont Hospital, Dublin, Not set

SLRON- St Luke's Radiation Oncology Network, Dublin, Not set

St. James's Hospital, Dublin, Not set

University Hospital Galway, Galway, Not set

Karolinska Institutet and Karolinska University Hospital, Stockholm, Not set

The Royal Bournemouth Hospital, The Royal Bournemouth And Christchurch Hospitals NHS Foundation, Bournemouth

Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Box 279(s4), Cambridge Biomedical Camp, Cambridge

Velindre Cancer Centre, Velindre NHS Trust, Velindre Road, Whitchurch, Cardiff

University Hospitals Coventry & Warwickshire, Clifford Bridge Road, Walsgrave, Coventry

Hull and East Yorkshire Hospitals NHS Trust, Castle Hill Hospital,, Cottingham, East Riding Of Yorkshire

Portsmouth Hospitals NHS Trust, Southwick Hill Road, Cosham, Hampshire

Mount Vernon Cancer Centre, E & N Hertfordshire NHS Trust, Rickmansworth Road, Northwood, Middlesex

Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham

Oxford University Hospital NHS Trust Churchill Hospital, Headington, Oxfordshire

University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Division A Cancer Care, Mp307, T, Southampton

Royal Surrey County Hospital, Guildford, Surrey

Worcestershire Royal Hospital, Worcestershire Oncology Centre, Charles Hastings Way, Worcester

Belfast Health and Social Care Trust, Northern Ireland Cancer Centre, Belfast CityHospital, Belfast, Not set

The Clatterbridge Cancer Centre NHS Foundation Trust, Birkenhead, Wirral, Not set

University Hospitals Bristol NHS Foundation Trust, Bristol, Not set

University Hospital Plymouth NHS Trust, Derriford Hospital, Derriford Road, Crownhill, Plymouth, Not set

NHS Lothian, Edinburgh Cancer Centre,, Edinburgh, Not set

Beatson West of Scotland Cancer Centre, Glasgow, 1056 Great Western Road, Not set

Imperial College Healthcare NHS Trust St Mary's Hospital, London, Not set

The Newcastle upon Tyne Hospital NHS Foundation TrustFreeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne, Not set

Royal Preston Hospital, Sharoe Garoo Lane, Fulwood, Preston, Not set

Conditions: Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours, Junctional Tumours, Oesophageal Cancer

Register for Updates

Learn More ›

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

NCT03665441

Completed

This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have measurable disease.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/27/2022

Locations: Arizona Cancer Center, Scottsdale, Arizona +15 locations

Conditions: Pancreatic Adenocarcinoma

Register for Updates

Learn More ›

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

NCT04060342

Terminated

This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/17/2022

Locations: UCSF Medical Center at Mission Bay, San Francisco, California +7 locations

Conditions: Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma

Register for Updates

Learn More ›

Biolimus A9™ (BA9™) Drug Coated Balloon (DCB) Study

NCT04079192

Unknown

The study is a Prospective, Randomized, Non-Inferiority Trial to Determine the Safety and Efficacy of the BA9™ Drug Coated Balloon for the Treatment of In-Stent Restenosis. It is a First-in-Man Trial.

Gender:

ALL

Ages:

Between 18 years and 90 years

Trial Updated:

08/09/2022

Locations: Heart Center, Segeberger Kliniken, Bad Segeberg, Not set +14 locations

Conditions: Coronary Artery Disease, In-Stent Restenosis

Register for Updates

Learn More ›

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

NCT00347412

Completed

The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC). Earlier clinical trials in NSCLC showed that patients treated with NOV-002 in combination with chemotherapy had a better response (their tumors got smaller in one United States Phase 1/2 trial) than patients who received chemoth... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/19/2022

Locations: Northwest Alabama Cancer Center, Muscle Shoals, Alabama +74 locations

Northwest Alabama Cancer Center, Muscle Shoals, Alabama

Sharp Memorial Hospital, San Diego, California

University of Chicago Medical Center, Chicago, Illinois

Northern Indiana Cancer Research Consortium, South Bend, Indiana

St. Agnes Hospital, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota

Park Nicollet Clinic - Cancer Center St. Louis Park, Saint Louis Park, Minnesota

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Cleveland Clinic Foundation Taussig Cancer Center, Cleveland, Ohio

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

South Texas Institute of Cancer, Corpus Christi, Texas

William Osler Health Center, Brampton, Ontario

Humber River Regional Hospital, Weston, Ontario

Jewish General Hospital, Montreal, Quebec

Laval Hospital, Sainte-Foy, Quebec

Barzilai Medical Center, Ashkelon, Not set

Lin Clinic, Haifa, Not set

Meir Medical Center, Kfar-Saba, Not set

Institute of Oncology, Petach Tikva, Not set

Sheba Medical Center, Ramat Gan, Not set

Assaf Harofeh Hospital, Zerifin, Not set

Azienda Ospedaliera Treviglio Caravaggio, Bergamo, Not set

Azienda Ospedaliera Careggi, Firenze, Not set

Sondrio Hospital, Sondrio, Not set

Oddzial Pulmonologiczny z Pododdzialem Chemioterapii, Bystra, Not set

Samodzielny Publiczny Szpital Kliniczny N°.1, Gdansk, Not set

Oddzial Chemioterapii Pomorskie Centrum Onkologii,, Gdynia, Not set

Katedra Onkologii Akademii Medycznej w Lodzi, Lodz, Not set

Oddzial Chemioterapii Zaklad Opieki Zdrowotnej MSWiA, Olsztyn, Not set

Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy Oddzial III, Otwock, Not set

Wielkopolskie Centrum Chorob, Poznan, Not set

Oddzial Gruzlicy I Chorob Pluc I P, Prabuty, Not set

Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie w Warszawie, Warsaw, Not set

Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Warszawa, Not set

S.C. Oncomed SRL, Timisoara, Timis County

Institute of Oncology, Department of Medical Oncology II, Bucharest, Not set

Institute of Oncology Cluj-Napoca, Cluj-Napoca, Not set

Institute of Oncology, Cluj-Napoca, Cluj-Napoca, Not set

Craiova Emergency Clinical County Hospital, Craiova, Not set

Arkhangelsk Regional Clinical Oncology Center, Arkhangelsk, Not set

Chelyabinsk Regional Oncology Center, Chemotherapy Department, Chelyabinsk, Not set

Clinical Oncology Center, Chemotherapy Department, Kazan, Not set

Omsk Regional Clinical Oncology Center, Omsk, Not set

Orenburg Regional Clinical Oncology Center, Orenburg, Not set

Stavropol Regional Clinical Oncology Center, Pyatigorsk, Not set

Oncology Center, Hematology Department, Sochi, Not set

Leningrad Regional Clinical Hospital, Department of Thoracic Surgery, St. Petersburg, Not set

City General Hospital #2, City Center of Intensive Pulmonology and Thoracic Surgery, St. Petersburg, Not set

St. Petersburg Pavlov State Medical University under the Federal Agency for Healthcare and Social Development, St. Petersburg, Not set

City Clinical Oncology Center, Thoracic Department, St. Petersburg, Not set

Stavropol Regional Clinical Oncology Center, Chemotherapy Department, Stavropol, Not set

Tambov Regional Oncology Center, Chemotherapy Department, Tambov, Not set

Kazan Oncology Center, Tatarstan, Not set

Voronezh Regional Clinical Oncology Center, Voronezh, Not set

Clinical Hospital Center Bezanijska kosa, Belgrade, Not set

Clinical Center Nis, Clinic for Lung Diseases "Knez Selo", Nis, Not set

Institute of Lung Diseases Sremka Kamenica, Sremska Kamenica, Not set

Hospital Clinic i Provincial de Barcelona, Barcelona, Not set

Hospital Mutua de Terrassa, Terrassa, Not set

Kantonales Spital Sursee-Wolhusen, Sursee, Not set

Cherkasy Regional Oncology Center, Cherkassy, Not set

Public Treatment and Prophylaxis Institution: Chernihiv Regional Oncology Center, Chernihiv, Not set

City General Hospital #4, Dnipropetrovsk, Not set

Regional Oncological Center, Ivano-Frankivsk, Not set

S.P. Grigoryev Institute of Medical Radiology, Kharkiv, Not set

Oncology Institute under the Ukrainian Academy of Medical Sciences, Kyiv, Not set

Crimean Republican Clinical Oncology Center, Simferopol, Not set

Zakarpatsky Regional Oncological Clinical Center, Uzhorod, Not set

Anchor Unit, Aberdeen Royal Infirmary, Aberdeen, Scotland

Ninewells Hospital and Medical School Department of Cancer Medicine, Dundee, Scotland

St. Luke's Cancer Centre, Guildford, Surrey

Oncology Research, Nottingham City Hospital, Nottingham, Not set

Dorset Cancer Centre, Poole Hospital, Poole, Not set

Yeovil District Hospital NHS Foundation Trust, Higher Kingston, Somerset, Not set

Conditions: Non Small Cell Lung Cancer

Register for Updates

Learn More ›

Paclitaxel Treatment Options in United Kingdom

Match to Clinical Trials